SD: Specialized disclosure report
6-K: U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Takeda Pharmaceutical | 6-K: Notice Regarding Issuance of JPY Hybrid Bonds
Takeda Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4.8%)
Takeda Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(5.4%)
Takeda Pharmaceutical | 6-K: Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024
Takeda Pharmaceutical | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.7%)
Takeda Pharmaceutical | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Sumitomo Mitsui Trust Holdings, Inc.(5.5%)
Takeda Pharmaceutical | 6-K: Quarterly Securities Report For The Nine-month Period and Three-month Quarter Ended December 31, 2023
Takeda Pharmaceutical | 6-K: Takeda Announces Chief Financial Officer Succession
Takeda Pharmaceutical | 6-K: Summary of Financial Statements for the Nine-month Period Ended December 31, 2023
Takeda Pharmaceutical | 4: Statement of changes in beneficial ownership of securities-10% Owner TAKEDA PHARMACEUTICAL CO LTD
Takeda Pharmaceutical | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(6.6%)
Takeda Pharmaceutical | SC 13G: Statement of acquisition of beneficial ownership by individuals-Takeda Pharmaceutical Company Limited(5.2%),Takeda Ventures, Inc(5.2%)
Takeda Pharmaceutical | 6-K: Announcement of a company split (simplified absorption-type company split/short-form company split) with a wholly-owned subsidiary
Takeda Pharmaceutical | 6-K: Partial Amendment to Corporate Governance Report
Takeda Pharmaceutical | 6-K: The 147th (interim period) Business Report
Takeda Pharmaceutical | 6-K: Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA
Takeda Pharmaceutical | 6-K: Report of foreign private issuer (related to financial reporting)
No Data